Key result
SGLT2 inhibitors are consistently linked to lower rates of heart failure, arrhythmias, and mortality.
Why the study?
Do SGLT2 inhibitors reduce cardiotoxicity, heart failure events, and mortality in patients with type 2 diabetes mellitus undergoing potentially cardiotoxic antitumor therapy?
Do SGLT2 inhibitors reduce cardiotoxicity, heart failure events, and mortality in patients with type 2 diabetes mellitus undergoing potentially cardiotoxic antitumor therapy?
Observational evidence suggests SGLT2 inhibitors may provide significant cardioprotective benefits in patients with type 2 diabetes receiving cardiotoxic cancer therapies, warranting dedicated randomized trials.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for SGLT2 inhibitors in cardio-oncology; randomized trials needed before practice change.
Patients with type 2 diabetes and cancer represent a vulnerable population in whom antitumor therapy may exacerbate an already existing cardiometabolic predisposition to damage. Despite the fact that inhibitors of the sodium-glucose cotransporter 2 have significantly changed approaches to the prevention and treatment of heart failure and chronic kidney disease, their role in cardio-oncology remains insufficiently defined. In 8 retrospective cohort studies published between 2022 and 2026, the use of sodium-glucose cotransporter 2 inhibitors was consistently associated with a lower incidence of heart failure, hospitalizations for heart failure, arrhythmias, acute kidney injury, and all-cause mortality. Several cohorts also demonstrated favorable associations with overall survival and survival without disease progression, while the overall safety profile was comparable to that of control groups. These data support the hypothesis that sodium-glucose cotransporter 2 inhibitors may provide clinically significant cardiometabolic protection beyond glycemic control and left ventricular ejection fraction in oncology patients undergoing cardiotoxic therapy. However, the available evidence remains observational and is subject to the influence of residual confounding, systematic error related to the choice of therapy, as well as the heterogeneity of cancer types, antitumor regimens, and outcome definitions. In this regard, specially designed prospective randomized studies are needed to establish a cause-and-effect relationship, determine the optimal timing of administration and patient selection criteria, and assess long-term cardiovascular and oncological safety. The aim of this review is to summarize the available clinical data on the potential cardioprotective role of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus receiving potentially cardiotoxic antitumor therapy.
No takes yet. Share an insight, caveat, or question.
Sarkisyan et al. (2026) conducted a review in Type 2 diabetes mellitus and cancer undergoing potentially cardiotoxic antitumor therapy. Sodium-glucose cotransporter 2 (SGLT2) inhibitors vs. Control groups not receiving SGLT2 inhibitors was evaluated on Incidence of heart failure, hospitalizations for heart failure, arrhythmias, acute kidney injury, and all-cause mortality. Across 8 retrospective cohorts (2022-2026), SGLT2 inhibitors were consistently associated with lower rates of heart failure, arrhythmias, acute kidney injury, and all-cause mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: